Stockhead on MSN5 天
Biocurious: While other biotechs scratch around for cash, Clinuvel is accused of having too ...
With $200 million of cash on hand, Clinuvel's financial position is the envy of other biotechs. But not everyone is ... Read ...
The Australian Financial Review4 天
Clinuvel Pharmaceuticals Limited
Manufacture and commercially distribute its prescription pharmaceutical SCENESSE in the European Union and the USA for the treatment of the rare, genetic metabolic disorder EPP, research and ...
Morningstar1 个月
Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology ...
The Pavilion also charts CLINUVEL’s 20-year journey towards developing and commercialising SCENESSE®, the first and only treatment for the rare metabolic disease erythropoietic protoporphyria ...
pharmaphorum1 年
NICE won't budge on rejection of rare disease drug
The UK's cost-effectiveness agency NICE has delivered its final verdict on Clinuvel's Scenesse, a treatment for a rare skin disorder that causes extreme sensitivity to light, and it isn't good ...
TipRanks on MSN20 天
CLINUVEL CEO Takes Temporary Leave; Operations to Continue Uninterrupted
Discover stocks' market position with detailed competitor analyses.The latest update is out from Clinuvel Pharmaceuticals Limited ( (AU:CUV) ). CLINUVEL Pharmaceuticals announced that CEO Dr.
The Australian Financial Review10 天
Clinuvel Pharmaceuticals Limited
Manufacture and commercially distribute its prescription pharmaceutical SCENESSE in the European Union and the USA for the treatment of the rare, genetic metabolic disorder EPP, research and ...